【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the Next-Generation Biologics Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biological Drugs
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2016-2026
3.1 The Next-Generation Biologics Market 2015
3.1.1 Development of the Next-Generation Biologics Market 2008-2015
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2015
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2015
3.2 The Next-Generation Biologics Market 2016-2026
3.2.1 Growth Drivers for Biological Drug Revenues 2016-2026
3.2.2 The Next-Generation Biologics Market Forecast 2016-2026
3.2.3 Product Launches in All Sectors to Drive Market Growth 2016-2026
3.2.4 Next-Generation Biologics: Market Restraints 2016-2026
3.2.5 Rising Market Shares for Next-Generation Insulins 2016-2026
4. Leading National Submarkets for Next-Generation Biologics 2016-2026
4.1 Leading National Submarkets for Next-Generation Biologics, 2015
4.1.1 National Submarket Forecasts 2016-2026
4.1.2 How Will National Submarket Shares Change to 2026?
4.2 Rising Disease Incidence in Important Markets 2016-2026
4.3 Approval of Next-Generation Biologics in Leading National Submarkets
4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2016-2026
4.4.1 US Submarket Forecast 2016-2026
4.5 Next-Generation Biologics in Japan 2016-2026
4.5.1 National Expertise in Stem Cell Research
4.5.2 Japanese Submarket Forecast 2016-2026
4.6 Next-Generation Biologics in Leading EU Countries 2016-2026
4.6.1 Regenerative Medicine Development in the EU
4.6.2 Market Access for Next-Generation Biologics in the EU
4.6.3 Germany: Submarket Forecast 2016-2026
4.6.4 France: Submarket Forecast 2016-2026
4.6.5 UK: Submarket Forecast 2016-2026
4.6.6 Italy and Spain: Submarket Forecasts 2016-2026
4.7 Next-Generation Biologics in Emerging Markets 2016-2026
4.7.1 Next-Generation Biologics Development in Emerging Countries
4.7.2 Chinese Submarket Forecast 2016-2026
4.7.3 Indian Submarket Forecast 2016-2026
5. Next-Generation Antibodies: Submarket Outlooks 2016-2026
5.1 Strategies for Improving Antibody Therapies
5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
5.1.2 Engineering Antibodies for Improved Potency
5.1.3 Bispecific Antibodies
5.2 Next-Generation Antibody Therapy Submarket
5.3 Next-Generation Antibody Therapy Submarket 2016-2026
5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2016-2026
5.3.2 Blockbuster Potential Will Drive Growth to 2026: Kadcyla, Adcetris and Cosentyx
5.3.3 Next-Generation Antibodies: Submarket Restraints 2016-2026
5.4 Antibody-Drug Conjugates (ADC) Submarket 2016-2026
5.4.1 Antibody-Drug Conjugates Submarket Forecast 2016-2026
5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2016-2026
5.4.2 What Will Drive Growth for ACDs to 2026?
5.4.3 A Long Pipeline of ADCs in Clinical Development
5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
5.4.3.3 CDX-011: Potential for Accelerated Approval in Breast Cancer
5.5 Engineered Antibodies Submarket 2016-2026
5.5.1 Engineered Antibodies Submarket Forecast 2016-2026
5.5.1.1 Gazvya Will Lead the Submarket in 2026
5.5.2 Portfolio Management to Drive Growth 2016-2026
5.5.3 Engineered Antibodies Pipeline 2016
5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
5.6 Bispecific Antibodies Submarket 2016-2026
5.6.1 Bispecific Antibodies Submarket Forecast 2016-2026
5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2016-2026
5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2016
5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody
6. Antibody Fragments and Novel Antibody-like Drugs: Commercial Potential 2016-2026
6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
6.1.2 There are Advantages to Using Fragments and Novel Scaffolds
6.2 Antibody Fragment and ALP Submarket 2016-2026
6.2.1 Antibody Fragment and ALP Submarket Forecast 2016-2026
6.2.2 Pharma is Investing Strongly in Antibody Fragments and ALPs
6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2026
6.3 Outlook for Next-Generation Antibody Fragments 2016-2026
6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2016-2026
6.3.2 One Platform Leads the Pipeline in 2016
6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
6.4 The Antibody-Like Protein Submarket 2016-2026
6.4.1 Antibody-Like Protein Submarket Forecast 2016-2026
6.4.2 Four ALPs in Clinical Development in 2016
6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
6.5 Will Next-Generation Immunotoxins Change the Market to 2026?
6.5.1 Challenges With First Generation Immunotoxins
6.5.2 Fusion Protein Conjugates: Pipeline 2016
6.5.2.1 Moxetumomab Pasudotox
6.5.3 Humanised Immunotoxins
6.5.3.1 Using Granzyme B in Immunotoxins
6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
7. Next-Generation Insulin Submarket: Outlook 2016-2026
7.1 Strategies for Next-Generation Insulin Development
7.1.1 Reformulating Insulin for Convenient Administration
7.1.1.1 Oral Insulin
7.1.1.2 Inhaled Insulin
7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
7.2 Next-Generation Insulin Submarket 2016-2026
7.2.1 Tresiba: Approved in the EU and Japan
7.2.1.1 Tresiba: Revenue Forecast 2016-2026
7.3 Next-Generation Insulin Submarket 2016-2026
7.3.1 Next-Generation Insulin Submarket Forecast 2016-2026
7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2016-2026
7.3.3 Next-Generation Insulin Submarket Restraints 2016-2026
7.3.3.1 Biosimilar Insulins are Available Since 2015
7.4 Oral Insulin Submarket 2016-2026
7.4.1 Oral Insulin Submarket Forecast 2016-2026
7.4.2 Oral Insulin: Submarket Drivers and Restraints 2016-2026
7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2016
7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
7.4.3.5 Novo Nordisk: NN-1953
7.5 Ultra-Rapid Acting Insulin Submarket 2016-2026
7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2016-2026
7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2026?
7.5.2 Other Submarket Drivers and Restraints 2016-2026
7.5.3 Ultra-Rapid Acting Insulin Pipeline 2016
7.5.3.1 FlAsp (Novo Nordisk)
7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
7.5.3.3 Halozyme Therapeutics
7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
7.6 Ultra-Long Acting Insulin Submarket 2016-2026
7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2016-2026
7.6.2 Revenue Growth Driven by Uptake of Tresiba
7.6.3 Ultra-Long Acting Insulin Pipeline 2016
7.6.3.1 Toujeo: Sanofi’s Next-Generation Insulin Analogue
7.6.3.2 LY2605541 (Eli Lilly)
7.6.3.3 LAPS-Insulin
8. Next-Generation Developments for Other Recombinant Proteins 2016-2026
8.1 Defining Next-Generation for Other Recombinant Protein Sectors
8.1.1 Next-Generation Interferon Beta: Plegridy Revenue Forecast 2016-2026
8.1.1.1 Plegridy May Compete With Other Long-Acting Interferon Beta Therapies 2016-2026
8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2016
8.2 Next-Generation Recombinant Coagulation Factors 2016-2026
8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2016-2026
8.2.2 Submarket Drivers and Restraints 2016-2026
8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2016-2026
8.2.3.1 Fused Factors: Biogen Idec’s Eloctate and Alprolix
8.2.3.2 Baxter’s BAX 855
8.2.3.3 CSL Behring’s rlX-FP: Albumin-Bound Coagulation Factors
8.2.3.4 Bayer’s BAY94-9027
8.2.3.5 Novo Nordisk’s N8-GP for Haemophilia A
8.2.3.6 Novo Nordisk’s N9-GP for Haemophilia B
8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
8.3 Next-Generation Growth Hormones 2016-2026
8.3.1 Next-Generation Growth Hormone Submarket Forecast 2016-2026
8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormone 2016-2026
8.3.3 Long-Acting Growth Hormones
8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
8.3.3.2 Prolor Biotech/OPKO Health
8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
9. Regenerative Medicine: Commercial Outlook 2016-2026
9.1 The Regenerative Medicine Submarket in 2015
9.1.1 Defining Regenerative Medicine
9.2 The Regenerative Medicine Submarket: Revenue Projections 2016-2026
9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2016-2026
9.3 The Stem Cell Therapies Submarket 2016-2026
9.3.1 Prochymal (Mesoblast) for GvHD
9.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
9.3.1.2 A Note on Stem Cell Transplants
9.3.2 Stem Cell Therapies Submarket Forecast 2016-2026
9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2016-2026
9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
9.3.4 Stem Cell Therapies Late-Stage Pipeline 2016
9.3.4.1 Cx601 (TiGenix)
9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
9.3.4.4 StemEx (Gamida Cell)
9.4 Outlook for Tissue Engineering 2016-2026
9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
9.4.1.1 Apligraf Leads the Wound Repair Submarket
9.4.1.2 Organogenesis Markets Apligraf and Dermagraft from 2014
9.4.2 Tissue Engineering Submarket Forecast 2016-2026
9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2016-2026
9.4.4 Future Developments in Cartilage Repair: Pipeline 2016
9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
9.4.5.1 Engineered Skin
9.4.5.2 Engineered Veins
9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9.5 The Gene Therapies Submarket 2016-2026
9.5.1 Glybera Approved and Set for Launch in the EU
9.5.2 Gene Therapies Submarket: Revenue Projections 2016-2026
9.5.3 Glybera’s Approval Driving Submarket Growth Since 2014
9.5.4 There are More Than Five Gene Therapies in Late-Stage Development
9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
9.5.4.2 TVEC (Amgen)
9.5.4.3 Generx (Cardium Therapeutics)
9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
10. Next-Generation Biologics: Industry Trends 2016-2026
10.1 Next-Generation Biologics: Market Strengths 2016
10.2 Next-Generation Biologics: Market Weakness 2016
10.3 The Next-Generation Biologics Market: STEP Analysis 2016-2026
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2016-2026
10.3.3 Economic Pressures 2016-2026
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2016-2026
10.4 Next-Generation Biologics: Development Trends 2016-2026
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2016-2026
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Research Interviews from Our Survey
11.1 Dr Edwin Moses, CEO, Ablynx
11.1.1 Ablynx
11.1.2 Ablynx’s Pipeline and Nanobody Technology
11.1.3 On Caplacizumab
11.1.4 Challenged with Current Biological Therapies
11.1.5 The Next-Generation Biologics Market, 2016-2026
11.2 Dr Mike Romanos, CEO, Crescendo Biologics
11.2.1 Crescendo Biologics
11.2.2 The Benefits in Antibody Fragment Therapies
11.2.3 Treatment of Inflammation Indications with Antibody Fragments
11.2.4 Crescendo’s Fragment Pipeline
11.2.5 Development and Production Platforms for Antibody Therapies
11.2.6 Crescendo’s Humabody ADCs and Multi-Specific T-Cell Engagers
11.2.7 CB001, A Topical Biologic
11.2.8 The Next-Generation Biologics Market, 2015-2025
11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann, VP of Research; Dr Kouros Motamed, VP, Strategic Alliances and Clinical Communications; George Uy, EVP and CCO
11.3.1 Sorrento Therapeutics Inc.
11.3.2 Sorrento’s Pipeline
11.3.3 Drivers and Restraints for Next-Generation Biologics
11.3.4 The Next-Generation Biologics Market, 2015-2025
11.4 Dr Fredrik Frejd, CSO, Affibody
11.4.1 Affibody
11.4.2 Challenges with Current Biological Therapies
11.4.2.1 Current Half-Life Extension Technologies
11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
11.4.4 Focus on Inflammation and Autoimmune Diseases
11.4.5 Development of SOBI002
11.4.6 Regulatory Challenges with Novel Biologics
12. Conclusions from Our Research and Analysis
12.1 The Next-Generation Biologics Market Will Grow Strongly to 2026
12.2 Next-Generation Antibody Development Will Lead the Market
12.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
12.4 Leading Regional Markets
12.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics
【レポート販売概要】
■ タイトル：次世代生物学的製剤の世界市場2016-2026■ 英文：Next-Generation Biologics Market 2016-2026
■ 発行日：2016年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN60626
■ 調査対象地域：グローバル
- 韓国の滅菌器市場見通し（～2021）South Korea Sterilization Equipment Market Outlook to 2021 Summary GlobalData’s new report, "South Korea Sterilization Equipment Market Outlook to 2021", provides key market data on the South Korea Sterilization Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Chemical Sterilizers, Physical St …
- 自動車用ブレーキ・バイ・ワイヤ（BBW）装置の世界市場2017-2021About Automotive Brake-By-Wire SystemsBBW refers to the facility of controlling the brakes in a vehicle through electrical means, rather than the involvement of more traditional mechanical linkages. BBW can be of two kinds by end intent: it may be so designed to supplement the existing braking effort, or it may function as a standalone braking system by itself. BBW is currently used in a wide vari …
- ギア（歯車）製造の世界市場：ウォームギア、ベベルギア、スパーギアAbout Gear Manufacturing A gear is a rotating machine that enables the transmission of torque through meshing of cut teeth or cogs with another toothed part or rack. The ttransmission occurs by synchronous working of two or more gears using mechanical force to achieve the desired output and thus act as a simple machine. Gears are transmission devices that require human effort for operation, and ar …
- 患者安全及びリスク管理ソフトウェアの世界市場予測（～2024年）“The patient safety and risk management solutions market is projected to grow at a CAGR of 11.2%.”The global patient safety and risk management solutions market is projected to reach USD 2.2 billion by 2024 from USD 1.3 billion in 2019, at a CAGR of 11.2% during the forecast period. Increasing need to improve patient safety & patient outcomes in the healthcare industry in line with patient safety …
- 牛肉の世界市場：部位別（ブリスケット、すね肉、腰肉）別、屠殺方法別、地域別、セグメント予測The global beef market size is expected to reach USD 383.5 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 3.1% CAGR during the forecast period. Growing awareness regarding beef as a major source of protein is expected to drive the market. Beef and veal have higher protein content compared to chicken, pork, turkey, and lamb. Surging awareness associated with c …
- アディソン病（Addison’s Disease）：グローバル臨床試験レビュー（2014年上半期）Addison's Disease (Primary or Chronic Adrenal Insufficiency) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Addison's Disease (Primary or Chronic Adrenal Insufficiency) Global Clinical Trials Review, H1, 2014" provides data on the Addison’s Disease (Primary or Chronic Adrenal Insufficiency) clinical trial scenario. This report provides elemental information an …
- Calvalley Petroleum Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Calvalley Petroleum Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Calvalley Petroleum Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential …
- 世界におけるバイオポリマー/バイオプラスチック市場動向及び予測（～2018）Biopolymers have found wide acceptance in various industries, on account of its distinguished environment friendly properties. On the basis of application areas, the market of biopolymers can be broadly segmented into packaging, bottles, fibers, agriculture, automotive, and others. Though packaging and bottles are the major biopolymers applications and serve an array of industries due to their var …
- 空港照明システムの世界市場：エアサイド照明、ターミナル照明、ランドサイド照明About Commercial Airport Lighting Airport lighting systems are essential for the safety and security of passengers, cargo, and aircraft. Constantly evolving technology has enabled airport authorities meet the safety norms set by the FAA. They help aircraft land and take off, even in poor natural lighting or bad weather. Airports around the world are currently upgrading to energy efficient LED ligh …
- ディーゼル商用車向け選択接触還元法（SCR）の世界市場2016-2020About Selective Catalytic Reduction SCR is used for controlling the emission levels of Nitrogen oxide from diesel engines. These are fitted in the exhaust system of the vehicles. SCR is a system that converts nitrogen oxides into nitrogen, carbon dioxide, and water. The system uses diesel exhaust fluid (DEF), which is essentially a liquid reductant agent that is injected into the exhaust stream of …
- 世界のコネクティッド・カー市場Consumers demands and mandates (both existing and expected) are the major drivers for the connected car market. Most of the major economies have already introduced one mandate or the other such as eCall in Europe and GLONASS in Russia. No wonder most of the industry experts opine that the connected car is all set to be the next big thing in the automotive industry. Future generations will rely mor …
- データセンター用ブレード・サーバの世界市場The global data center blade server market is estimated to grow at a CAGR of 10.25% from 2014 to 2019. Although the mature markets (such as the U.S. and the U.K.) hold larger share in the data center blade server market, the Asia-Pacific region is expected to grow at the highest CAGR of 14.19% during the forecast period. Increasing computing density, business optimization needs, and converged solu …
- 皮革製品の世界市場：フットウェア、バック、財布、かばんTechnavio's market research analyst predicts the leather goods industry to grow at a CAGR of around 4% during the forecast period. The rise in export of leather is the primary driver for the growth of this market. For instance, during 2014, the US exported hides, skins and semi-processed leather which generated a revenue of around USD 3 billion. China, Taiwan, Korea, Mexico, and the European count …
- 自動売買システム（システムトレード）の世界市場2016-2020About Automated Trading Systems The automated trading systems are also referred to as algorithmic trading or mechanical trading systems where it allows the trader to establish specific rules for both trade entries and trade exits. They are generally programmed in a way so that they can be automatically executed through computer systems. The entry and exit in the trade is based on the moving averag …
- 世界における小型自動車用ドアモジュール市場（2008-2028）This latest just-auto report edition offers a global review of the OE door modules sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE door modules market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prosp …
